Skip to content

Inspection Record

Fresenius Kabi Oncology Limited — FDA 483 Findings

US FDAInspected 2023-10-10Published 2024-12-05 11 findingsAseptic processing and sterility assuranceLaboratory and QC controlsEquipment and facilityDocumentation and recordsQuality unit oversightDeviation, CAPA, and investigation

Inspectors Justin A Boyd · Anastasia M ShieldsThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of diug products pmpo1ting to be sterile are not established and followed.

2Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.

3Laboratory and QC controls

Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

4Equipment and facility

Written procedures are not established for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.

5Laboratory and QC controls

Established test procedures are not documented at the time ofperformance.

6Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions.

7Documentation and records

Batch production and control records do not include complete information relating to the production and control of each batch.

8Laboratory and QC controls

Laboratory records do not include complete data derived from all tests, examinations and assay necessary to assure compliance with established specifications and standards.

9Quality unit oversight

The responsibilities and procedures applicable to the quality control unit are not fully followed.

10Deviation, CAPA, and investigation

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.

11Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2024-12-05. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Fresenius Kabi Oncology Limited company profile — full historyAll US FDA findings US FDA documents, 2024 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.